In vivo treatment with a monoclonal antibody to interferon-gamma neither affects the survival nor the incidence of lupus-nephritis in the MRL/lpr-lpr mouse

Ferdinando Nicoletti, Pierluigi Meroni, Roberto Di Marco, Wilma Barcellini, Maria Orietta Borghi, Marisa Gariglio, Angela Mattina, Sebastiano Grasso, Santo Landolfo

Research output: Contribution to journalArticlepeer-review

Abstract

The effects of the in vivo treatment with a mAB (DB-1) that neutralizes mouse IFN-gamma on the development of the SLE-like syndrome in MRL/lpr-lpr (MRL-lpr) mice were studied. The results show that the i.p. administration of 2.6 mg/week of DB-1 from the 12th to the 20th week of age neither affected the survival nor the incidence and severity of lupus nephritis in MRL-lpr mice. This study argues against the pathogenic relevance of IFN-gamma in this experimental model of human SLE.

Original languageEnglish
Pages (from-to)11-16
Number of pages6
JournalImmunopharmacology
Volume24
Issue number1
DOIs
Publication statusPublished - 1992

Keywords

  • Autoimmune disease
  • IFN-gamma, anti-gamma-IFN mAB
  • MRL-lpr mouse
  • Systemic lupus erythematosus

ASJC Scopus subject areas

  • Pharmacology

Fingerprint

Dive into the research topics of 'In vivo treatment with a monoclonal antibody to interferon-gamma neither affects the survival nor the incidence of lupus-nephritis in the MRL/lpr-lpr mouse'. Together they form a unique fingerprint.

Cite this